Last reviewed · How we verify
NCT05989074
All Women Comparing Self-expanding ALLEGRA Valve to Any Other Balloon-expandable Valve
NA trial testing ALLEGRA TAVI System TF in Aortic Stenosis, Severe in 130 participants. Status unknown.
31 August 2025
Quick facts
| Lead sponsor | Ceric Sàrl |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 130 |
| Start date | 1 February 2024 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
Drugs / interventions tested
- ALLEGRA TAVI System TF
- Ballon-expandable valve system
Conditions studied
- Aortic Stenosis, Severe — all drugs for Aortic Stenosis, Severe →
Sponsor
Ceric Sàrl
Who can join
75 and older, female only, with Aortic Stenosis, Severe. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study is aimed to demonstrate that the self-expandable Allegra TAVI system provides lower mean gradient assessed by TTE compared to balloon-expandable valve systems in a female patient population with symptomatic severe aortic stenosis
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The TAVI Dilemma: Balloon-Expandable or Self-Expanding Transcatheter Heart Valve-Interpreting Current Evidence for Personalized Valve Selection.
Vlachakis PK, Theofilis P, Kachrimanidis I, Soulaidopoulos S, et al · · 2025 · cited 2× · PMID 40869477 · DOI 10.3390/jcm14165651
Verify or expand the search:
- PubMed search for NCT05989074
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Stenosis, Severe
Currently open trials in the same condition.
- NCT06818110 — The CardioFit Trial: Exercise Training Before Aortic Valve Surgery · NA · active not recruiting
- NCT06596460 — A Study to Obtain Imaging Data in 40 Patients Having Transcatheter Aortic Valve Implantation (TAVI) · NA · recruiting
- NCT06377449 — Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients · NA · recruiting
- NCT06129799 — Exercise CMR in (p)LF-LG AS · recruiting
- NCT05751577 — TRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial · NA · active not recruiting
Other Ceric Sàrl trials
Trials by the same sponsor.
- NCT07348341 — Coronary Laser Atherectomy Registry From an International Taskforce · not yet recruiting
- NCT06887413 — TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial. · NA · not yet recruiting
- NCT06235554 — Feasibility Study Evaluating the Safety and Efficacy of the Renal Stimulation by Direct Wire Pacing, During Renal Denerv · NA · unknown
- NCT04679805 — Physio PCI: Impact of Coronary Angioplasty on Non-hyperaemic Pressure Ratio in Patients With Coronary Artery Disease · terminated
- NCT04431661 — CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05989074 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ceric Sàrl
- Last refreshed: 12 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989074.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing